v3.25.2
Share-Based Payment (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment [Abstract]  
Schedule of Financial Statements for Services Received from Employees and Officers

The expense recognized in the financial statements for services received from employees and officers is shown in the following table:

    Year ended December 31,   
    2024     2023     2022  
    USD in thousands  
                         
Equity-settled share-based payment plans     2,070       7,115       10,516  
Schedule of Number of Share Options and the Weighted Average Exercise Prices

The following table presents the changes in the number of share options and the weighted average exercise prices of share options:

 

    2024    2023 
    Number of
options		    Weighted
average
exercise
price		    Number of
options		    Weighted
average
exercise
price		 
                     
Share options outstanding at beginning of year   37,157    100.4    84,415    160.2 
Share options granted during the year   -    -    12,824    11.4 
Share options exercised during the year   (680)    0.5    14,588    12.8 
Share options forfeited during the year   (132)    0.4    955    0.4 
Share options expired during the year   (19,912)    165.1    44,538    179.1 
                     
Share options outstanding at end of year   16,433    28.4    37,158    100.1 
                     
Share options exercisable at end of year   16,104    25.2    35,969    99.5 
Schedule of Status of RSUs

A summary of the status of RSUs under the Plan as of December 31, 2024 and changes during the relevant period ended on that date is presented below:

 

    Number of
RSU		 
      
Outstanding at beginning of year*   161,569 
Granted   - 
Vested   (43,697) 
Forfeited and cancelled   (13,094)
      
Outstanding at end of year   104,778 

 

*This includes shares granted with performance obligations which were not fulfilled as of December 31, 2024.
Schedule of Total Equity-Based Compensation Expense

The total equity-based compensation expense related to all of the Company’s equity-based awards recognized for the years ended December 31, 2024, 2023 and 2022, was comprised as follows:

 

   Year ended December 31, 
   2024   2023   2022 
             
Cost of revenues   -    35    206 
Research and development expenses   (11)   3,010    603 
Sales and marketing expenses   (32)   211    1,504 
General and administrative expenses   2,113    3,859    8,203 
                
Total share-based payment   2,070    7,115    10,516